{"id":41,"date":"2023-11-22T15:37:28","date_gmt":"2023-11-22T15:37:28","guid":{"rendered":"https:\/\/ncrndev.org.uk\/?page_id=41"},"modified":"2023-11-22T15:37:28","modified_gmt":"2023-11-22T15:37:28","slug":"ncrn-and-industry","status":"publish","type":"page","link":"https:\/\/ncrndev.org.uk\/index.php\/ncrn-and-industry\/","title":{"rendered":"NCRN and Industry"},"content":{"rendered":"

NCRN and Industry<\/p>\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n
\nThe\u00a0NIHR CRN CC\u00a0is tasked with developing a world-class infrastructure to ensure that high-quality research funded by both commercial and non-commercial organisations receives the support it needs to succeed.<\/p>\n

Such support will include investment in the expansion of dedicated clinical research staff within the NHS, and the development of standard procedures to ensure consistent best practice at\u00a0network study sites through both study set up and conduct.<\/p>\n

The NIHR CRN CC\u00a0 has established a dedicated Industry team to address the specific challenges and pressures faced by the healthcare industry in successfully delivering their research and development projects through the NHS. The NIHR CRN CC\u00a0 Industry team is working closely with the healthcare industries, the Department of Health, and NHS Trusts in identifying barriers to the delivery of clinical research in the UK, and formulating solutions and strategies to overcome these.<\/p>\n

The following leaflet gives a brief introduction to these themes:<\/p>\n

How can industry engage with\u00a0NIHR CRN CC\u00a0?<\/a>\u00a0PDF file, 1.2 MB<\/strong><\/p>\n

The NCRN Industry team are working in close collaboration with the NIHR CRN CC\u00a0 and the Pharmaceutical Industry to bring commercial oncology studies into the national NIHR Portfolio.<\/p>\n

Professor Rick Kaplan \u2013 Associate Director<\/strong><\/p>\n

Dr Matthew Cooper \u2013 Principal Fellow \u2013 Clinical Trials<\/strong><\/p>\n

Miss Julie Kitcheman \u2013 Industry Portfolio Administrator<\/strong><\/p>\n

The Industry team can be contacted at\u00a0\u00a0<\/a>industry@ncrn.org.uk<\/a><\/p>\n

Further detailed information on the NIHR CRN CC\u00a0 Working with Industry process can be found at the main NIHR CRN CC\u00a0Industry page\u00a0http:\/\/www.ukcrn.org.uk\/index\/industry.html<\/a>.<\/p>\n

Industry Trials Feasibility and Adoption Process<\/strong>
\nAs for all other research taken on by the networks, industry-contract studies must be formally adopted by the NIHR CRN CC\u00a0. The NIHR CRN CC\u00a0 industry team has developed a process specifically for the adoption of industry-contract studies which has been informed by discussions with industry through the UKCRC Industry Road Map Group. The process takes into account the needs of industry, in particular, the time constraints faced by companies. Therefore, the Industry Trials Adoption Process is a highly streamlined process in order to meet the tight timelines often required by industry.<\/p>\n

Level 1 Feasibility \u2013 top line national feedback from individuals<\/strong>
\nWe aim to deliver a decision about the suitability of study to be conducted in the UK within 2 weeks. This rapid assessment considers if the UK has the appropriate subject population for a study and whether the treatment plans differs fundamentally from standard UK treatment pathway(s).<\/p>\n

Level 2 Feasibility \u2013 detailed site level feedback including adoption onto the UKCRN Portfolio.<\/strong>
\nIf Level 1 Feasibility has not previously been conducted, it will be performed at the beginning of this process, to rapidly access the suitability of the study to be conducted in the UK.<\/p>\n

Following this, an in-depth feasibility including adoption onto the NIHR CRN CC\u00a0 Portfolio will be performed. This will provide information about potential sites\/investigators; assess anticipated patient numbers and the availability of research resources including skills, facilities and equipment. We aim to complete this process within 4 weeks.<\/p>\n